Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 1.00 |
| ▸ | RET | P07949 | 5/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 0.97 |
| ▸ | EPHB2 | P29323 | 3/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.76 |
| ▸ | FLT1 | P17948 | 2/20 | 0.75 |
| ▸ | GAK | O14976 | 2/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | JAK3 | P52333 | 1/20 | 0.75 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.75 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.75 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.75 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.75 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.75 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.74 |
| ▸ | CLK1 | P49759 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515328 | 1.00 | EGFR (1.00) | EGFRKDRRETLCKEPHB2 | |
| Hydrochloric Acid SCHEMBL5475737 | 0.99 | EGFR (1.00) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL1387182 | 0.97 | EGFR (0.94) | EGFRKDRRETLCKEPHB2 | |
| Hydrochloric Acid SCHEMBL8807895 | 0.96 | EGFR (0.95) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL13604741 | 0.92 | EGFR (0.85) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL30891782 | 0.91 | EGFR (0.83) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL22338291 | 0.91 | EGFR (0.83) | EGFRKDRRETLCKEPHB2 | |
| Hydrochloric Acid SCHEMBL8814111 | 0.91 | EGFR (0.85) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL13604745 | 0.90 | EGFR (0.82) | EGFRKDRRETLCKEPHB2 | |
| SCHEMBL12779087 | 0.90 | EGFR (0.82) | EGFRKDRRETLCKEPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441199-B2 | Cells exhibiting neuronal progenitor cell characteristics and methods of making them | SANBIO, INC. (US) | 2016-09-13 | — | — | US | claimed |
| US-20150267169-A1 | CELLS EXHIBITING NEURONAL PROGENITOR CELL CHARACTERISTICS AND METHODS OF MAKING THEM | SANBIO, INC. (US) | 2015-09-24 | — | — | US | claimed |
| US-20140065133-A1 | JAK/STAT INHIBITORS AND MAPK/ERK INHIBITORS FOR RSV INFECTION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-03-06 | — | — | US | claimed |
| US-8592368-B2 | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-11-26 | — | — | US | claimed |
| WO-2011109217-A2 | METHODS OF TREATING OR PREVENTING RNA POLYMERASE DEPENDENT VIRAL DISORDERS BY ADMINISTRATION OF JAK2 KINASE INHIBITORS | IMMUNODIAGNOSTICS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| EP-1572075-A4 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL KINASE ACTIVITY | SUPERGEN INC (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1875900-A2 | JAK/STAT pathway inhibitors and the use thereof for the treatment of osteoarthritis | GENZYME CORPORATION (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1572075-A3 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL KINASE ACTIVITY | SuperGen, Inc. (US) | 2005-10-13 | — | — | EP | claimed |
| EP-1572075-A2 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL KINASE ACTIVITY | SuperGen, Inc. (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050159385-A1 | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection | SOUTH FLORIDA, UNIVERSITY OF | 2005-07-21 | — | — | US | claimed |
| US-20040127453-A1 | Method for treating diseases associated with abnormal kinase activity | SUPERGEN, INC. | 2004-07-01 | — | — | US | claimed |
| WO-2003065995-A2 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL KINASE ACTIVITY | SUPERGEN, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | claimed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | claimed |
| WO-2023250140-A1 | STAT3 INHIBITOR TO TREAT SUBARACHNOID HEMORRHAGE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-12-28 | — | — | WO | disclosed |
| US-11059815-B2 | Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-07-13 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059815-B2 | Synthesis of small molecule histone deacetylase 6 degraders, compounds formed thereby, and pharmaceutical compositions containing them | HDAC1, HDAC6, HDAC3 | EGFR 894/4885KDR 2696/4885RET 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.